

At Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year.
1 empleados en Seqirus han revisado Seqirus en varias dimensiones de la cultura corporativa, compartiendo sus opiniones entre calificaciones ejecutivas hasta el ritmo en el trabajo. La última revisión fue hace el mes pasado.
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 3,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries.




Dejaremos saber a Seqirus que estos interesado en trabajar en la compania, manteniendo tu identidad personal anonima. Comparably le dara la oportunidad a Seqirus de contratarte. Cuando haya un puesto de trabajo que sea adecuado, haremos que se produzca la coincidencia.
En 2019, Seqirus aplico para 4 Visas H1B. De los permisos de trabajo solicitados, 100% fueron aprobados.
Seqirus tiene un total de 3000 empleados
Resultado de aplicaciones H1B
Estos datos se calcularon utilizando datos de fuentes de rendimiento de OFLC.
| 0% | Promoters |
|---|---|
| 100% | Passives |
| 0% | Detractors |


Envíales una invitación para valorar la cultura de la empresa.